Provision of naloxone to injection drug users as an overdose prevention strategy: Early evidence from a pilot study in New York City

Provision of naloxone to injection drug users as an overdose prevention strategy: Early evidence from a pilot study in New York City
复制标题

DOI:
10.1016/j.addbeh.2005.07.020
复制
发表时间:
2006-05-01
影响因子:
4.4
通讯作者:
Rosenthal, David M.
Rosenthal, David M.
中科院分区:
医学2区
文献类型:
--
作者:
Galea, Sandro;Worthington, Nancy;Rosenthal, David M.

文献摘要

被引文献

相似文献

简介:纳洛酮是一种阿片拮抗剂,可以避免阿片过量服用的道德,长期以来一直是欧洲和美国一些城市吸毒者的处方药。然而,在美国的同行评审文献中,几乎没有关于纳洛酮分配计划及其可行性的记录证据。方法:在纽约市注射器交换计划中实施了一项试点过量预防和逆转计划。我们在基线、参与者返回处方补充时以及基线评估后 3 个月评估了人口统计数据、药物使用和过量用药史、经验和行为。结果:招募了 25 名参与者。 22 名 (88%) 参与者在前 3 个月内成功随访;其中,11 名 (50%) 参与者报告在随访期间总共目睹了 26 次用药过量。最近发生的 17 起服药过量事件中,有 10 次服用了纳洛酮;所有服用纳洛酮的人都活了下来。讨论:注射吸毒者注射纳洛酮作为全面的药物过量预防策略的一部分是可行的,并且可能是大规模减少药物过量死亡的可行方法。 (c) 2005 Elsevier Ltd. 保留所有权利。
Introduction: Naloxone, an opiate antagonist that can avert opiate overdose morality, has long been prescribed to drug users in Europe and in a few US cities. However, there has been little documented evidence of naloxone distribution programs and their feasibility in the peer reviewed literature in the US.Methods: A pilot overdose prevention and reversal program was implemented in a New York City syringe exchange program. We assessed demographics, drug use, and overdose history, experience, and behavior at baseline, when participants returned for prescription refills, and 3 months after baseline assessment.Results: 25 participants were recruited. 22 (88%) participants were successfully followed-up in the first 3 months; of these, 11 (50%) participants reported witnessing a total of 26 overdoses during the follow-up period. Among 17 most-recent overdoses witnessed, naloxone was administered 10 times; all persons who had naloxone administered lived.Discussion: Naloxone administration by injection drug users is feasible as part of a comprehensive overdose prevention strategy and may be a practicable way to reduce overdose deaths on a larger scale. (c) 2005 Elsevier Ltd. All rights reserved.